[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575140":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":32,"locations":31,"responsibleParty":42,"collaborators":31,"id":44,"slug":31,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":31,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":31,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":31,"overallStatus":61,"whyStopped":31,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":31},{"fullName":5,"class":6},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"prepubertal children of short stature","prepubertal children of short stature with different Initial doses of PEG-rhGH",[12],"Drug: PEG-rhGH",{"label":14,"type":6,"description":15,"interventionNames":16},"pubertal children of short stature","pubertal children of short stature with different Initial doses of PEG-rhGH with or without GnRHa treatment",[12,17],"Drug: GnRHa",[19,27],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","PEG-rhGH","1= 0.2mg\u002Fkg\u002Fweek Initial doses of PEG-rhGH 2=0.22mg\u002Fkg\u002Fweek Initial doses of PEG-rhGH",[9,14],[25,26],"1","2",{"type":20,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"GnRHa","1. pubertal children of short stature without GnRHa treatment\n2. pubertal children of short stature with GnRHa treatment",[14],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Xiaoou Shan","CONTACT","+86 1377779922","2296037178@qq.com",{"name":39,"role":35,"phone":40,"phoneExt":31,"email":41},"Mengjie Yang","+86 159 5871 0186","540718644@qq.com",{"type":43,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100575140",false,"NCT06768411","The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children","Inclusion Criteria:\n\n1. Patients with short stature or a genetic target height below 2 standard deviations;\n2. Individuals who are pre-pubertal (Tanner stage I) and pubertal (Tanner stages II-IV).\n3. Legal guardians consenting to participate in the study and signing informed consent forms.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity reactions to the investigational product or related products;\n2. Presence of severe systemic diseases;\n3. Patients with malignant tumors;\n4. Participation in any other clinical trial and receipt of drug or non-drug interventions within the 3 months prior to screening;\n5. Patients unable to adhere to follow-up or receive treatment as scheduled;\n6. Other circumstances in which the investigator deems the patient unsuitable for inclusion in this clinical trial.","ALL","1 Year","16 Years",{"count":53,"type":54},240,"ESTIMATED","INTERVENTIONAL",[57],"NA","This study is dedicated to addressing the lack of research on the most effective dosage of long-acting growth hormone for children with short stature. By employing clinical trial design, we are committed to investigating the therapeutic benefits and safety profiles associated with varying doses of long-acting growth hormone. Our ultimate goal is to offer clinicians more precise treatment guidance and assist patients in attaining optimal growth and developmental outcomes.",[60],"Short Stature","NOT_YET_RECRUITING","2025-01-06",{"date":64,"type":65},"2025-01-10","ACTUAL",{"date":67,"type":54},"2025-01-15",{"date":69,"type":54},"2027-06-01",{"name":5,"class":6}]